Radiopharm Theranostics Limited · ASX:RAD
Radiopharm Theranostics — Shareholder Meeting (November 2022)
16 slides from Radiopharm Theranostics's shareholder meeting presentation, Nov 16, 2022
Slide 1: Annual General Meeting November 2022
For personal use only Annual General Meeting NOVEMBER 2022
Slide 2: Important Notice and Disclaimer
IMPORTANT NOTICE AND DISCLAIMER The information in this presentation does not constitute personal investment advice. The presentation is not intended to be comprehensive or provide all For personal use only information required by investors to make an informed decision on any investment in Radiophar
Slide 3: Significant progress since IPO
Significant progresses since IPO towards our ambition of BECOMING THE RECOGNIZED LEADER IN FIGHTING CANCER THROUGH INNOVATIVE RADIOPHARMACEUTICAL THERAPIES For personal use only BoD & MANAGEMENT STRENGTHENED PORTFOLIO EXPANSION Two new BoD members, COO, VP From 4 to 6 technologies, with Clinical Dev
Slide 4: Radiopharmaceutical therapy has the potential to transform the cancer treatment paradigm
RADIOPHARMACEUTICAL THERAPY HAS THE POTENTIAL TO TRANSFORM THE CANCER TREATMENT PARADIGM For personal use only $85B 90 CAGR 22% Worldwide Oncology Market in 2025 80 I/O Therapies ~$290B; CAGR 5y (2020-2025) = 13% 70 60 Chemo and Targeted Therapies 50 ~$190B; CAGR 5y (2020-2025) = 9% RADIOPHARMACEUTI
Slide 5: Prostate theranostics: most recent successful targeted radiopharmaceuticals
PROSTATE THERANOSTICS: MOST RECENT SUCCESSFUL TARGETED RADIOPHARMACEUTICALS Female breast For personal use only Prostate Lung and bronchus Colon and rectum Imaging Therapeutic Melanoma of the skin Non-Hodgkin lymphoma Urinary bladder Combined analysts’ peak Analysts’ peak sales Kidney and renal pelv
Slide 6: F18-Pivalate for imaging and treatment of brain metastasis
F18-PIVALATE FOR IMAGING AND TREATMENT OF BRAIN METASTASIS For personal use only F18-PIVALATE Selectively targets fatty acid synthetase which is LINKER overexpressed in tumors but not normal brain cells CANCER CELL TARGET: RADIOACTIVE Fatty acid synthetase ISOTOPE: 18F to SEE TARGETING MOLECULE: piv
Slide 7: Pivalate delivers positive Phase II data in brain metastasis trial
Pivalate Delivers Positive Phase II Data In Brain Metastasis Trial RESULTS For personal use only RAD 101 Phase IIa Clinical Trial: F18-pivalate PET showed high uptake regardless of F18-pivalate PET/MRI Imaging origin of primary tumor Patients with one or more cerebral metastases from different prima
Slide 8: Positive pivalate trial data in brain metastasis
POSITIVE PIVALATE TRIAL DATA IN BRAIN METASTASIS Pivalate Platform Next Steps: For personal use only RAD 101 (Imaging) RAD 102 (Therapeutic) Imaging Proof of Concept supports therapeutic Scientific Advisory Board analysis of Phase IIa data to development determine most appropriate clinical use (YE 2
Slide 9: Brain metastasis market opportunity
BRAIN METASTASIS MARKET OPPORTUNITY Prostate cancer is the largest radiopharmaceutical imaging indication that received FDA approval Best proxy for assessing Radiopharm’s potential market opportunity for its brain metastasis indication For personal use only Cancer New US Cases Eligible New Price Pot
Slide 10: Six platforms, well differentiated molecules
SIX PLATFORMS, WELL DIFFERENTIATED MOLECULES One Of The Deepest Pipelines In Radiopharmaceutical Therapies For personal use only Pivalate αVβ6 Integrin Nano-mAb PSA-mAb DUNP19 PTPμ Small molecule Peptide Sd mAb mAb mAb Peptide Target: Target: Target: Target: Target: Target: Fatty Acid αVβ6 integrin
Slide 11: Portfolio prioritization
PORTFOLIO PRIORITIZATION For personal use only Imaging and 9 molecules Multiple Therapeutic use indications 20+ clinical development trials PRIORITIZATION FILTERS Market potential as Imaging or Therapeutic Clinical Trial Probability of Success Disease Area Size & Unmet Need (First to market or Best
Slide 12: Current portfolio priorities
CURRENT PORTFOLIO PRIORITIES For personal use only RAD CODE MOLECULE INDICATION DX / TX ISOTOPE PRECLINICAL PHASE I PHASE II PHASE III NOTES IMAGING RAD 101 pivalate Brain Mets Dx F18 Positive Phase II readout Oct 2022 Phase I planned Q4 2022. Clinical RAD 301 Integrin αVβ6 Pancreatic Dx Ga68 data a
Slide 13: MD Anderson & RAD joint venture funded in Sept 2022
MD ANDERSON & RAD JOINT VENTURE FUNDED IN SEPT 2022 For personal use only 49% RADIOPHARM 51% VENTURES LLC Mandate: Develop novel radiopharmaceutical therapies Preclinical and Phase I Management Team, Regulatory Strategy, Clinical Development Intellectual Property 4 Molecules, R&D, Preclinical, Manuf
Slide 14: Scientific Advisory Board: two new members added
SCIENTIFIC ADVISORY BOARD: two new members added For personal use only PROF ERIC ABOAGYE DR SUSAN BRADY c c Pivalate PTPμ DR JOHANNES NOTNI DR DAVID ULMERT αVβ6 Integrin DUNP 19 PSA-mAb DR HONG HOI TING PROF SARA HURVITZ Nano-mAb RADIOPHARM THERANOSTICS LTD 2022 | 14
Slide 15: Becoming a recognized leader in fighting cancer through innovative radiopharmaceutical therapies
BECOMING A RECOGNIZED LEADER IN FIGHTING CANCER THROUGH INNOVATIVE RADIOPHARMACEUTICAL THERAPIES For personal use only Highly prospective portfolio of World-class management team radiopharmaceuticals for with radiopharmaceutical imaging & therapeutic applications expertise Clinical stage cancer targ
Slide 16: Contact us
For personal use only CONTACT US Riccardo Canevari Paul Hopper CEO & MANAGING DIRECTOR Executive Chairman Radiopharm Theranostics Limited Radiopharm Theranostics Limited T +1 862 309 0293 T +61 406 671 515 E rc@radiopharmtheranostic.com E paulhopper@lifescienceportfolio.com W www.radiopharmtheranost
Radiopharm Theranostics — Shareholder Meeting (November 2022) on 6ix